AMGN

Institutions Shift Positions in Major Blue-Chip Stocks
Portfolio reshuffling boosts insurers and biotech; analysts back health names while P&G shows investor uncertainty.
Apr 17, 2026
5 min read
Amgen Rides Renewed GLP-1 Obesity Momentum
Amgen (AMGN) is now being treated in positioning as an emerging GLP-1 obesity and diabetes play, with investors increasingly framing the stock around its obesity pipeline rather than only its legacy...
Apr 9, 2026
1 min read
Amgen and Gilead Face Conflicting Valuation Signals
Market rallies clash with valuation models as analysts and DCFs disagree on biotech pricing.
Mar 12, 2026
5 min read
Investors Confront Conflicting Valuation Signals
Investors navigate mixed signals as AI and climate analytics reshape stock valuations and market momentum.
Feb 23, 2026
6 min read
Live Nation, PTC, AES Lead Busy Earnings and Energy News
Live Nation tops forecasts on concert demand; PTC faces revenue dip; AES leads clean energy sales.
Feb 19, 2026
5 min read
Biopharma Leaders Map Growth at JPM 2026
Biopharma firms eye strong 2026 growth with new launches and rising sales boosting profits.
Jan 13, 2026
8 min read
Comprehensive Valuation Insights on Leading Stocks in Late 2025
Key stocks show mixed valuations; undervalued pharma firms contrast with overvalued finance giants amid sector shifts.
Nov 30, 2025
6 min read
Dow Hits Record High Amid Shutdown Optimism, Tech Stocks Slide
Dow surges on shutdown hopes; tech stocks dip as investors shift to defensive sectors.
Nov 12, 2025
5 min read